Cipla Limited — Levofloxacin Exporter Profile
Indian Pharmaceutical Exporter · #10 for Levofloxacin · $1.3M export value · DGFT Verified
Cipla Limited is the #10 Indian exporter of Levofloxacin with $1.3M in export value and 25 verified shipments. Cipla Limited holds a 1.7% market share in Levofloxacin exports across 3 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Levofloxacin Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Levofloxacin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| YEMEN | $478.7K | 13 | 51.8% |
| SOUTH AFRICA | $331.8K | 7 | 35.9% |
| YEMEN, DEMOCRATIC | $100.0K | 2 | 10.8% |
| MAURITIUS | $13.4K | 3 | 1.4% |
Cipla Limited exports Levofloxacin to 4 countries. The largest destination is YEMEN accounting for 51.8% of Cipla Limited's Levofloxacin shipments, followed by SOUTH AFRICA (35.9%) and YEMEN, DEMOCRATIC (10.8%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Levofloxacin from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI ANAA | YEMEN | $226.2K | 5 |
| MEDPRO PHARMACEUTICA (PTY) LIMITED | SOUTH AFRICA | $131.8K | 3 |
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI | YEMEN | $110.6K | 5 |
| MEDPRO PHARMACEUTICA (PTY) LTD | SOUTH AFRICA | $100.0K | 2 |
| AL JABAL DRUGS & MEDICAL APPLIANCES | YEMEN, DEMOCRATIC | $100.0K | 2 |
| AL JABAL DRUGS & MEDICAL APPLIANCE | YEMEN | $100.0K | 2 |
| MEDPRO PHARMACEUTICA (PTY) LTD, | SOUTH AFRICA | $50.0K | 1 |
| MEDPRO PHARMACEUTICA (PTY) LTD. | SOUTH AFRICA | $50.0K | 1 |
| MEDICA PHARMACEUTICAL INDUSTRIES L | YEMEN | $41.9K | 1 |
| IBL LTD (HEALTHACTIV) | MAURITIUS | $8.1K | 2 |
Cipla Limited supplies Levofloxacin to 11 buyers globally. The largest buyer is CIPLAMEDICA PHARMACEUTICAL INDUSTRI ANAA (YEMEN), followed by MEDPRO PHARMACEUTICA (PTY) LIMITED (SOUTH AFRICA) and CIPLAMEDICA PHARMACEUTICAL INDUSTRI (YEMEN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Levofloxacin Export Value and How Much Does Cipla Limited Contribute?
India exported $36.0M worth of Levofloxacin through 6,304 shipments from 699 suppliers to 150 countries, serving 1,543 buyers globally. Cipla Limited contributes $1.3M to this total, accounting for 1.7% of India's Levofloxacin exports. Cipla Limited ships Levofloxacin to 4 countries through 11 buyers.
What Is the Average Shipment Value for Cipla Limited's Levofloxacin Exports?
Cipla Limited's average Levofloxacin shipment value is $50.0K per consignment, based on 25 shipments totaling $1.3M. The largest destination is YEMEN (51.8% of Cipla Limited's Levofloxacin exports).
How Does Cipla Limited Compare to Other Indian Levofloxacin Exporters?
Cipla Limited ranks #10 among 699 Indian Levofloxacin exporters with a 1.7% market share. The top 3 exporters are MACLEODS PHARMACEUTICALS LTD ($9.5M), MICRO LABS LIMITED ($5.0M), SENTISS PHARMA PRIVATE LIMITED ($4.7M). Cipla Limited processed 25 shipments to 3 destination countries.
What Levofloxacin Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TAVALOXX 750 TABLETS (LEVOFLOXACIN HEMIHYDRATE)(PACK SIZE:1X5X44620 PACK=223100NOS)NOS | $131.8K | 3 |
| TAVALOXX 750 TABLETS (LEVOFLOXACIN HEMIH | $100.0K | 2 |
| LEVOBACT INFUSION ( LEVOFLOXACIN HEMIHYDRATE INJECTION LIQUID (INFUSION)5MG/ML) | $100.0K | 2 |
| LEVOBACT INFUSION ( LEVOFLOXACIN HEMIHYDRATE INJECTION LIQUID (INFUSION)5MG/ML) ( INV. QTY. 33600 PACK 1 X 10 | $100.0K | 2 |
| TAVALOXX 500 TAB (LEVOFLOXACIN HEMIHYDRATE 500MG) [34040(PACKS)X1X5'S] | $50.0K | 1 |
| TAVALOXX 500 TAB (LEVOFLOXACIN HEMIHYDRATE 500MG)[PAC SIZE:1X5X33580 PAC=167900NOS] | $50.0K | 1 |
| LEVOBACT 500 TABLET LEVOFLOXACIN HEMIHYDRATE 500MG INV.QTY.3933 PACK 10X10S=393300 NOS | $45.9K | 1 |
| LEVOBACT 500 TABLET LEVOFLOXACIN HEMIHYDRATE 500MG INV.QTY.3905 PACK 10X10S=390500 NOS | $45.5K | 1 |
| LEVOBACT 500 TABLET LEVOFLOXACIN HEMIHYDRATE 500MG INV.QTY.3900 PACK 10X10S=390000 NOS | $45.5K | 1 |
| LEVOBACT 500 TABLET LEVOFLOXACIN HEMIHYDRATE 500MG INV.QTY.3889 PACK 10X10S=388900 NOS | $45.3K | 1 |
Cipla Limited exports 20 distinct Levofloxacin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TAVALOXX 750 TABLETS (LEVOFLOXACIN HEMIHYDRATE)(PACK SIZE:1X with 3 shipments worth $131.8K.
Regulatory Requirements: Exporting Levofloxacin to Key Markets
What Cipla Limited must comply with to export Levofloxacin to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Levofloxacin Exporters?
Exporters ranked immediately above and below #10 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | MEDCELL PHARMA | $1.3M | 26 | 5 | $50.0K |
| 12 | AJANTA PHARMA LIMITED | $1.3M | 81 | 15 | $16.0K |
| 10 | CIPLA LIMITED ★ | $1.3M | 25 | 3 | $50.0K |
| 13 | WEXFORD LABORATORIES PRIVATE LIMITED | $1.1M | 88 | 7 | $12.0K |
| 14 | MSN LABORATORIES PRIVATE LIMITED | $743.1K | 102 | 7 | $7.3K |
Cipla Limited ranks #10 among 699 Indian Levofloxacin exporters. Average shipment value of $50.0K compared to the market average of $51.5K. The closest competitors by value are MEDCELL PHARMA and AJANTA PHARMA LIMITED.
Which Indian Ports Ship Levofloxacin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 670 | 10.6% |
| DELHI AIR CARGO ACC (INDEL4) | 633 | 10.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 620 | 9.8% |
| DELHI AIR | 531 | 8.4% |
| NHAVA SHEVA SEA (INNSA1) | 439 | 7.0% |
| JNPT/ NHAVA SHEVA SEA | 240 | 3.8% |
| JNPT | 186 | 3.0% |
| Bombay Air | 164 | 2.6% |
Geopolitical & Trade Policy Impact on Cipla Limited's Levofloxacin Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Levofloxacin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Levofloxacin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Levofloxacin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 25 individual customs records matching Cipla Limited exporting Levofloxacin, covering 20 formulations to 4 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 150+ countries, 1,543+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Levofloxacin Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Levofloxacin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Levofloxacin Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Levofloxacin. For current shipment-level data, contact TransData Nexus.